Prestige Consumer's First Quarter Exclusively In OTCs Is Prelude To Growth
This article was originally published in The Pink Sheet
Executive Summary
Prestige Consumer's sales in its latest quarter were lifted by gas relief and ear wax products, but the gains were offset "revenue recognition" accounting changes and slower sales of BC and Goody's as supplies of the analgesics transitioned to new packaging.
You may also be interested in...
Dramamine, Nix Drive Prestige Consumer Sales
Consumers’ OTC drug choices extend beyond pain relievers, heartburn remedies and allergy formulations, Prestige Consumer Healthcare points out as it announces reported revenues up 0.8% to $279.3m in its latest quarter.
Prestige Sales Flat, Net Income Up
Net income for its FY 2020 second quarter grew 8.1% to $33.3m and diluted earnings per share were up to 65 cents from 59 cents in the year-ago period.
Prestige's Monistat, Summer's Eve Brands Key Drivers In Consumer Health Focus
BC and Goody's OTC acetaminophen formulations perhaps are the firm's most known consumer health brands but they account for 12% of its revenues while its Monistat and Summer's Eve brands drove 27% of its sales in its latest quarter. The feminine hygiene brands' contribution, says a Jefferies analyst , will only grow with the firm selling its household care brands to focus entirely on the consumer health market.